Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma
Via an accelerated approval, Lynozyfic is indicated to treat adult patients with relapsed or refractory multiple myeloma (r/r MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody.
Regeneron's drug joins two fellow BCMAxCD3 bispecific antibodies already at market in the US – Johnson & Johnson's (J&J) Tecvayli and Pfizer's Elrexfio.
Despite playing catch-up with its rivals, Regeneron's product offers a dosing advantage. Lynozyfic, which stimulates T-cells to recognise and destroy cancer cells, can be administered monthly after 24 weeks of therapy, depending on how well the patient responds.
Meanwhile, J&J's Tecvayli can be given every two weeks in patients who show a good response after at least six months, and Elrexfio has the same dosing interval from week 25 onward. Lynozyfic also has a fortnightly dosing schedule for patients starting from week 14.
Regeneron's Phase I/II Linker-MM1 trial (NCT03761108) with Lynozyfic demonstrated an objective response rate of 70% in 80 patients with MM. Tecvayli and Elrexfio had response rates of 63% and 56% in their respective trials, though direct comparisons are difficult to draw without a head-to-head study.
Boxed warnings are common for T-cell directing drugs, and Lynozyfic is no different. It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity.
It is unclear how Regeneron will challenge J&J and Pfizer in MM, who both reached the market first but have less convenient dosing options.
Justin Holko, Regeneron's senior vice-president for global oncology/haematology commercial business, told Pharmaceutical Technology: 'We don't comment on sales figures or market share, but believe Lynozyfic has the potential to provide significant benefit to multiple myeloma patients, society and the healthcare system.'
Tecvayli generated $549m in 2024 while Elrexfio secured $133m. MM is the second most common blood cancer, and revenue for these drugs is expected to skyrocket. Tecvayli, for example, is forecast to reach nearly $4.5bn in annual sales by 2031, according to GlobalData's Pharma Intelligence Center. Similar analysis predicts Lynozyfic will generate $707m in sales by that year, a lower figure primarily due to Regeneron's later market entry.
International Myeloma Foundation's interim CEO Diane Moran said: '[Lynozyfic] provides appropriate multiple myeloma patients and their care teams with a novel patient-centric treatment option that includes a dosing schedule that can be adapted based on patient response. We appreciate Regeneron's continued research to further advance treatment for this community.'
"Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
FDA may revoke Pfizer COVID-19 shot for young, healthy children.
The Food and Drug Administration may revoke authorization for Pfizer's COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine options ahead of the winter respiratory virus season. The possibility comes several months after President Donald Trump's Department of Health and Human Services began placing limits on COVID-19 vaccines. For the last four years, updated COVID-19 vaccines have been made available in the fall for most Americans before the cold sets in. The federal agency told Pfizer that it might not renew the emergency use authorization, or EUA, for the Pfizer-BioNTech COVID-19 vaccine Comirnaty for children ages 6 months through 4 years, according to a statement sent to USA TODAY. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a company spokesperson said. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine, which continues to demonstrate a favorable profile.' HHS spokesperson Andrew Nixon declined to predict what the agency might do. 'We do not comment on potential, future regulatory changes,' Nixon said. 'Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation.' In July, Moderna received full FDA approval for its COVID-19 vaccine for children 6 months to 11 years old who are at increased risk of contracting COVID-19. The vaccine, Spikevax, is expected to be available for eligible populations in the 2025-26 respiratory virus season. The Centers for Disease Control and Prevention still recommends older patients get vaccinated against COVID-19, as well as people whose immune systems have been weakened by illness or medical treatments such as chemotherapy. But if Pfizer loses its EUA, parents won't have the option to vaccinate their healthy young children. HHS Secretary Robert F. Kennedy Jr. has long sown doubt about a wide range of vaccines, while saying parents should be able to choose which vaccines their children should get. In late May, he announced that the COVID-19 vaccine for healthy children and healthy pregnant women was removed from the Centers for Disease Control and Prevention's immunization schedule. 'There's no evidence healthy kids need it today," Dr. Marty Makary, FDA commissioner, said in the May 27 video announcement posted to X. The American Academy of Pediatrics pushed back, saying at the time that the removal 'ignores independent medical experts and leaves children at risk.' Ending access to vaccination for healthy young children would strip families of choice, said Dr. Sean O'Leary, chair of the academy's committee on infectious diseases, in a May statement. 'Those who want to vaccinate may no longer be able to, as the implications for insurance coverage and access remain unclear," he said. This article originally appeared on USA TODAY: FDA might revoke Pfizer COVID-19 shot for children
USA Today
17 hours ago
- USA Today
FDA may revoke Pfizer COVID-19 shot for young, healthy children.
Parents won't be able to vaccinate their healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization. The Food and Drug Administration may revoke authorization for Pfizer's COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine options ahead of the winter respiratory virus season. The possibility comes several months after President Donald Trump's Department of Health and Human Services began placing limits on COVID-19 vaccines. For the last four years, updated COVID-19 vaccines have been made available in the fall for most Americans before the cold sets in. The federal agency told Pfizer that it might not renew the emergency use authorization, or EUA, for the Pfizer-BioNTech COVID-19 vaccine Comirnaty for children ages 6 months through 4 years, according to a statement sent to USA TODAY. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a company spokesperson said. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine, which continues to demonstrate a favorable profile.' HHS spokesperson Andrew Nixon declined to predict what the agency might do. 'We do not comment on potential, future regulatory changes,' Nixon said. 'Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation.' In July, Moderna received full FDA approval for its COVID-19 vaccine for children 6 months to 11 years old who are at increased risk of contracting COVID-19. The vaccine, Spikevax, is expected to be available for eligible populations in the 2025-26 respiratory virus season. The Centers for Disease Control and Prevention still recommends older patients get vaccinated against COVID-19, as well as people whose immune systems have been weakened by illness or medical treatments such as chemotherapy. But if Pfizer loses its EUA, parents won't have the option to vaccinate their healthy young children. HHS Secretary Robert F. Kennedy Jr. has long sown doubt about a wide range of vaccines, while saying parents should be able to choose which vaccines their children should get. In late May, he announced that the COVID-19 vaccine for healthy children and healthy pregnant women was removed from the Centers for Disease Control and Prevention's immunization schedule. 'There's no evidence healthy kids need it today," Dr. Marty Makary, FDA commissioner, said in the May 27 video announcement posted to X. The American Academy of Pediatrics pushed back, saying at the time that the removal 'ignores independent medical experts and leaves children at risk.' Ending access to vaccination for healthy young children would strip families of choice, said Dr. Sean O'Leary, chair of the academy's committee on infectious diseases, in a May statement. 'Those who want to vaccinate may no longer be able to, as the implications for insurance coverage and access remain unclear," he said.
The Hill
18 hours ago
- The Hill
FDA considers revoking Pfizer COVID vaccine for children under 5
The Food and Drug Administration is considering revoking the authorization of Pfizer's COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season. Pfizer's three-dose shot for children between 6 months and 5 years old has long been available under an emergency use authorization (EUA). But according to the company, the FDA is weighing ending that authorization. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' Pfizer told The Hill. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine which continues to demonstrate a favorable profile,' the company added. Pfizer expects the FDA to approve its vaccine for children ages 5 to 11 with the same limitations as Moderna and Novavax. The FDA in July approved Moderna's shot for children 6 months and older, but only if they have a health condition that puts them at increased risk for severe COVID-19. Novavax has never been approved for children under 12. Pfizer has had full FDA approval for its COVID-19 vaccine for individuals age 12 and older since 2022. It's not unusual for the FDA to revoke emergency authorization on a product if a competitor gains approval for an alternative, and Pfizer has not yet applied for full approval of its COVID-19 vaccine for the youngest age group. All COVID-19 vaccines were initially available only under emergency use authorizations— effectively special permissions given during an emergency if there are no FDA-approved alternatives available. But given the limitation on the Moderna shots, if Pfizer's authorization is pulled, healthy children under 5 years old will have no official options if their parents want to get them vaccinated. 'Parents already were struggling. We had parents, even last year, they had to drive two to three hours to get [COVID] vaccines for their kids. So already, access was an issue. Now it's just going to be abysmal,' said Fatima Khan, co-founder of the group Protect Their Future, which advocates for vaccine access for children. 'You're abandoning children right now … this is something that's so safe and so easy for them to just administer to our kids. Why can we not get it?' Khan said. In a statement to The Hill, the Department of Health and Human Services said it wouldn't comment on potential changes. 'The COVID-19 pandemic ended with the expiration of the federal public health emergency in May 2023. We do not comment on potential, future regulatory changes. Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation,' HHS spokesman Andrew Nixon said. In May, HHS Secretary Robert F. Kennedy Jr. said that the Centers for Disease Control and Prevention would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC then updated its immunization schedule to reflect that children with no underlying health condition 'may receive' COVID-19 vaccines after consulting with a health care provider. Kennedy has expressed personal antipathy towards the Moderna and Pfizer shots, calling them dangerous and unreliable. HHS also just announced it was pulling back on funding research involving the mRNA technology that was used to develop the vaccines in record time. State health officials said they have been told Moderna is ramping up supplies of its vaccine for the fall and will be able to meet demand if Pfizer's vaccine is no longer available for the youngest children. Providers who already pre-ordered Pfizer shots for the coming season will likely be able to switch to Moderna. But since the Moderna vaccine is only licensed for kids at risk of severe infection, pediatricians will have to offer them 'off label' for healthy kids with no guarantee it will be covered by insurance. 'We're hopeful that the clinical decision making allows them to request the vaccine and get it and have it covered by insurance. But it's just complicated,' said Claire Hannan, executive director of the Association of Immunization Managers, which represents state and local officials. 'The FDA just sort of went outside of the recommendation process in the way that it licensed the Moderna vaccine, and so there's a lot of confusion, and we're just sort of waiting for guidance from CDC on the ordering,' Hannan said. Infectious disease experts have said, and CDC data show, children under age 2 are at risk for severe COVID-19 infection even if they are otherwise healthy. Ayanna Bennett, director of the District of Columbia's Department of Health, said healthy kids should be able to live their best lives. If vaccination will keep them from getting seriously ill, it shouldn't be a question, she said. 'I want kids to not miss two weeks of school. I want kids not to be hospitalized, or in urgent care and miserable. We want them to be able to live their lives when there's no reason why they shouldn't,' Bennett told reporters during a briefing Wednesday. 'If I can prevent something, I should do it, and this is something where we absolutely have prevention available.'
